Mesalazine granules once-daily dose provides similar results to twice-daily dose in patients with active, left-sided ulcerative colitis.

The objective of the MOTUS study was to show non-inferiority of once-daily mesalazine versus twice-daily dosing for the induction of remission in active ulcerative colitis. As many patients with ulcerative colitis experience left-sided disease, the aim of the new sub analysis was to assess specifically the efficacy in patients with left-sided ulcerative colitis.
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news